-
Google establishes AI drug company Isomorphic Labs, headed by DeepMind CEO
Time of Update: 2022-01-06
In 2020, the company announced that it has developed a new generation of artificial intelligence system AlphaFold, which can accurately predict the structure of protein folding within a few days, solving a 50-year-old "major challenge" .
-
An elderly patient died after being treated with Biogen's Alzheimer's disease drug Aduhelm
Time of Update: 2022-01-06
According to the latest case summary report received by the US FDA as of the end of September, the FDA's Adverse Event Reporting System (FAERS) recorded a patient who died after receiving Aduhelm treatment .
At the dose recommended by the FDA, Aduhelm may cause ARIA cases, which has been learned from its clinical trials .
-
"Unlimited cancer types" therapy!
Time of Update: 2022-01-06
In May 2020, the FDA approved selpercatinib for the treatment of non-small cell lung cancer (NSCLC), medullary thyroid cancer, and thyroid cancer patients with RET gene fusion or mutation .
-
Gale and Corning Jerry reached an exclusive global development agreement for PD-L1 antiviral indications
Time of Update: 2022-01-06
Under the terms of the agreement, Corning granted Jerry song ceremony outside Greater China and developed exclusive worldwide commercialization rights and interests of ASC22, indications for all viral diseases, including hepatitis B, including .
-
Hetero and Beimei Pharmaceuticals launch antiviral drugs in China
Time of Update: 2022-01-05
Beijing, November 12, 2021/PRNewswire/ - Hetero, a world-renowned vertically integrated pharmaceutical organization, and Shenzhen Beimei Pharmaceuticals jointly announced that they have obtained oseltamivir phosphate from the Chinese drug regulatory agency, the National Medical Products Administration.
-
AbbVie IL-23 inhibitor gains second indication for treatment of psoriatic arthritis
Time of Update: 2022-01-05
▲Skyrizi's performance in the primary and secondary endpoints in two phase 3 clinical trials (picture source: reference [2])Reference materials:[1] AbbVie Expands Immunology Portfolio in the European Union with the European Commission Approval of Skyrizi® (risankizumab) for the Treatment of Adults with Active Psoriatic Arthritis.
-
East Sunshine Medicine is working hard!
Time of Update: 2022-01-05
Recently, Dongyang Sun Pharmaceutical's product line welcomes new progress: the application for the listing of 4 types of generic quetiapine fumarate tablets has entered the pending approval stage, sprinting to the fourth domestic market; 3.
-
Oculis' new experimental topical eye drops OCS-01 clinical phase III study completed the first batch of patients
Time of Update: 2022-01-05
Once approved, OCS-01 can greatly help patients with diabetic macular edema get more treatment options Hong Kong, November 16, 2021/PRNewswire/ - Oculis SA ("Oculis"), a biopharmaceutical company focused on clinical development and research, is pleased to announce that its Phase III clinical study called DIAMOND has completed the first batch of patient medications.
-
Genentech reaches approximately US$600 million in cooperation with oral bacteria to deliver therapeutic drugs
Time of Update: 2022-01-05
Novome’s proprietary genetically engineered microbial drugs (GEMMs) platform will be used to discover, modify, and develop bacterial strains that can express and deliver specific therapeutic drugs to lesions in the human intestine for the treatment of inflammatory bowel disease (IBD) And other diseases .
-
Sinopharm Hyundai Octreotide Acetate Injection passed the consistency evaluation of generic drugs
Time of Update: 2022-01-05
Octreotide acetate was originally developed by Novartis and was first marketed in the United States in 1988 .
-
The first IL-25 monoclonal antibody!
Time of Update: 2022-01-05
XKH001 is the first IL-25 monoclonal antibody independently developed by Xinkanghe with global intellectual property rights .
It is worth noting that in July 2021, Xinkanghe announced that XKH001 was approved by the FDA for phase I clinical trials, becoming the world's first FDA-approved clinical IL-25 inhibitor .
-
U.S. FDA lifts import ban on Huahai Pharmaceutical's southern Sichuan API production base
Time of Update: 2022-01-05
On November 17, Huahai Pharmaceutical issued an announcement stating that the company had recently received an official letter from the US FDA that the FDA had lifted the import ban on its southern Sichuan API production base .
-
Map-like atrophy treatment drugs!
Time of Update: 2022-01-05
In May 2021, Empaveli (pegcetacoplan) was approved by the US FDA for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) .
-
Viterilol RIP1 inhibitor SIR1-365 starts clinical trials in China
Time of Update: 2022-01-05
According to the official website of Viterilon, in animal experiments, inhibiting RIP1 kinase through small molecule drugs or gene editing can effectively prevent or reduce the development of a series of diseases, including multiple sclerosis (EAE model), Alzheimer's disease, amyotrophic lateral sclerosis, systemic inflammatory response syndrome .
-
Haisco's Class 1 innovative drug HSK31679 first applied for clinical treatment of hypercholesterolemia
Time of Update: 2022-01-05
HSK31679 tablet is a highly selective thyroid hormone β receptor (THR-β) agonist independently developed by Haisco.
Preclinical studies have shown that HSK31679 has good pharmacodynamic effects in hypercholesterolemia and NASH models, and has a good development prospect.
-
Xie Deren, independent director of Liaoning Chengda University, resigns
Time of Update: 2022-01-05
On November 16, Liaoning Chengda issued an announcement stating that the board of directors received an application for resignation from independent director Xie Deren on November 15 .
-
The domestically produced new crown drug is expected to be approved for conditional listing before the end of December
Time of Update: 2022-01-04
On November 22, according to the People’s Daily, the new crown drug BRII-196 and BRII-198 jointly developed by Tsinghua University, Shenzhen Third People’s Hospital and Tengsheng Bo Pharmaceutical has been unblinded in clinical phase III, and the drug delivery group is in treatment After 28 days, zero deaths were achieved, and 8 cases in the control group died.
-
Positive results in clinical trial of bispecific antibody for treatment of refractory HER2-positive breast cancer
Time of Update: 2022-01-04
Recently, Zymeworks announced that its bispecific antibody Zanidatamab targeting HER2, combined with chemotherapy, has shown encouraging results in a phase 1 clinical trial for the treatment of refractory HER2-positive breast cancer patients who have received multiple pre-treatments.
-
Watson Bio launches Phase IIIb clinical trial of new crown mRNA vaccine booster
Time of Update: 2022-01-04
ARCoVaX is an mRNA vaccine jointly developed by Abbio, Watson Bio and the Academy of Military Medicine to prevent new coronary pneumonia caused by SARS-CoV-2 infection .
-
The EU approves Qinlock's first fourth-line GIST drug has been launched in China
Time of Update: 2022-01-04
Zai Lab partner Deciphera Pharmaceuticals recently announced that the European Commission (EC) has approved the targeted anti-cancer drug Qinlock (Chinese trade name: Qingle®, generic name: ripretinib, Ripetinib) for fourth-line treatment of gastrointestinal tract GIST (GIST), the drug is specifically applicable to: Adult patients with advanced GIST who have previously received 3 or more kinase inhibitor treatments (including imatinib) .
